Abstract
This retrospective study was undertaken to determine the outcome of patients with non-seminomatous germ cell tumour who achieved a serological complete response but who had residual radiologic abnormalities upon completion of primary platinum-based chemotherapy. This was an analysis of 76 consecutive patients treated at Mount Vernon Hospital between 1983 and 1997. The patients were placed into two groups based upon whether they had surgical resection (surgery group, 48 patients) or observation (observation group, 28 patients) of residual radiologic masses on completion of initial chemotherapy (to enter the surgery group, complete surgical resection must have been achieved). The primary end-points were progression-free and overall survival. The percentage of patients alive with median follow-up 66 months was 90% for the surgery group and 80% for the observation group (P= 0.53, not significant). The percentage of patients continuously disease-free was 70% in the surgery group and 80% in the observation group (P= 0.31, not significant). In the small sub-group of patients with differentiated teratoma (TD) in the primary lesion who were observed, there was no excess risk of relapse or death. Patients who achieve a serological complete response after primary chemotherapy, but are left with ≤ 2 cm radiological masses that are not cystic and have responded, can be safely observed with diligent follow-up. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aass N, Klepp O, Cavallin-Shahl E, Dahl O, Wicklund H, Unsgaard B, Ahlstrom S and Fossa SD (1991) Prognostic factors in unselected patients with nonseminomatous testicular cancer: a multivariate analysis. J Clin Oncol 9: 818–826
Bajorin DF, Herr H, Motzer RJ and Bosl GJ (1992) Current perspectives of the role of adjunctive surgery in the combined modality therapy for patients with germ cell tumours. Semin Oncol 19: 148–158
Christmas TJ, Doherty AP, Rustin GJS, Seckl MJ and Newlands ES 1998a) Excision of residual masses of metastatic germ cell tumours after chemotherapy: the role of extraperitoneal surgical approaches. Br J Urol 81: 301–308
Christmas TJ, Smith GL and Kooner R 1998b) Vascular interventions during post-chemotherapy retroperitoneal lymph-node dissection for metastatic testis cancer. Eur J Surg Oncol 24: 292–297
Debono DJ, Heilman DK, Einhorn LH and Donohue JP (1997) Decision analysis for avoiding post chemotherapy surgery in patients with disseminated nonseminomatous germ cell tumours. J Clin Oncol 15: 1455–1464
Donohue JP and Rowland RG (1984) The role of surgery in advanced testicular cancer. Cancer 54: 2716–2721
Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, Williams S and Loehrer P (1987) Correlation of computerised tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137: 1176–1179
Fossa SD, Aass N, Ous S, Hoie J, Stenwig AE, Lien HH, Paus E and Kas P (1989) Histology of tumour residuals following chemotherapy in patients with advanced non-seminomatous testicular cancer. J Urol 142: 1239–1242
Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S and Giercksky KE (1992) Is post chemotherapy retroperitoneal surgery necessary in patients with non-seminomatous germ cell tumour and minimal residual tumour masses?. J Clin Oncol 10: 569–573
Gelderman WA, Koops HS, Sleijfer DT, Oosterhuis JW and Oldhoff J (1986) Treatment of retroperitoneal residual tumour after PVB chemotherapy of non-seminomatous testicular tumours. Cancer 58: 1418–1421
Hendry WF, A'Hern RP, Hetherington JW, Peckham MJ and Dearnaley DP (1993) Paraaortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol 71: 208–213
Horwich A, Mason MD and Hendry F (1995) Testicular tumours. In Oxford Textbook of Oncology, Peckham M, Pinedo H, Veronesi U (eds) pp 1407–1438, Oxford University Press: Oxford
International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603
Jaeger N, Weissbach L and Bussar-Maatz R (1994) Size and status of metastases after inductive chemotherapy of germ cell tumours. Indications for salvage operation. World J Urol 12: 196–199
Janetschek G, Hobisch A, Hittmair A, Holtl L, Peschel R and Bartsch G (1999) Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for stage IIB nonseminomatous testicular carcinoma. J Urol 161: 477–481
Jones WG, Stenning SP and Read G (1998) Long term follow up of unresected residual masses following platinum based chemotherapy for metastatic non-seminoma of the testis (MRC Study TE16): a preliminary report. In Germ Cell Tumours IV, Jones WG, Appleyard I, Harnden P, Joffe JK (eds) pp 269–275, John Libbey and Co Ltd: London
Kaplan E and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Levitt MD, Reynolds PM, Sheiner HJ and Byrne MJ (1985) Non-seminomatous germ cell tumour: residual masses after chemotherapy. Br J Surg 72: 19–22
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, McPherson K, Peto J and Smith PG (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1–39
Pugh RCB (1976) Testicular tumours. In Pathology of the Testis, Pugh RCB (ed) pp 149–159, Blackwell Science: Oxford
Rabbani F, Gleave ME, Coppin CM, Murray N and Sullivan LD (1996) Teratoma in primary testis tumour reduces complete response rates in retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of Stage IIb germ cell tumours with teratomatous elements. Cancer 78: 480–486
Sagalowsky AI, Ewart DH, Molberg K and Peters PC (1990) Prediction of mass histology after chemotherapy for advanced testis cancer. Urology 36: 537–542
Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, Jones WG, Newlands ES, Oliver RT, Stenwig AE and Wilkinson PM (1998) Residual masses post-chemotherapy for germ cell tumour: content, clinical features and prognosis. Cancer 83: 1409–1420
Steyerberg EW, Keizer HJ, Zwartendijk J, Van Rijk GL, van Groeninge S, Habbema JD and Stoter G (1993) Prognosis after resection of residual masses following chemotherapy for metastatic non-seminomatous testicular cancer: a multivariate analysis. Br J Cancer 68: 195–200
Steyerberg EW, Keizer HJ, Stoter G and Habbema JDF (1994) Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 30: 1231–1239
Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffer H, Mulders PF, Messemer JE, Ney K and Donohue JP (1995) Prediction of residual mass histology after chemotherapy for metastatic non-seminomatous germ cell tumour: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13: 1177–1187
Steyerberg EW, Keizer HJ, Messener JE, Toner GC, Schraffordt Koop SD, Gerl A, Sleijfer DT, Donohue JP and Habbema JD (1997) Residual pulmonary masses after chemotherapy for non-seminomatous germ cell tumour: prediction of histology. Cancer 79: 345–355
Steyerberg E, Keizer HJ and Habbema JDF (1998) Resection of small residual masses and evidence-based medicine. In Germ Cell Tumours IV, Jones WG, Appleyard I, Harnden P, Joffe JK (eds) pp 261–268, John Libbey and Co Ltd: London
Steyerberg EW, Marshall PB, Keizer HJ and Habbema JD (1999) Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis. Cancer 85: 1331–1341
Stomper P, Kalish L, Garnick M, Richie JP and Kantoff PW (1991) CT and pathologic predictive features of residual mass histologic findings after chemotherapy for non-seminomatous germ cell tumours: can residual malignancy or teratoma be excluded?. Radiology 180: 711–714
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Napier, M., Naraghi, A., Christmas, T. et al. Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours. Br J Cancer 83, 1274–1280 (2000). https://doi.org/10.1054/bjoc.2000.1416
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1416